

Determination of Antibiotic Resistance Pattern and frequency of *CTX-M*, *TEM*, and *SHV B*-Lactamase Encoding Genes among *Shigella* Isolates from Inpatients in Tehran, Iran

Shadi Beladi Ghannadi (MSc)

Department of Biology, Faculty of Science, Islamic Azad University Islamshahr Branch, Islamshahr, Iran

Maryam Ghane (PhD)

Department of Biology, Faculty of Science, Islamic Azad University Islamshahr Branch, Islamshahr, Iran

Laleh Babaeekhou (PhD)

Department of Biology, Faculty of Science, Islamic Azad University Islamshahr Branch, Islamshahr, Iran

Corresponding author: Maryam Ghane

Email: ghane@iaiu.ac.ir

Tel: +98-2156358105

Address: Islamic Azad University, Islamshahr Branch, Islamshahr, Iran

Received: 9 Jun 2018

Revised: 02 Dec 2018

Accepted: 2 Dec 2018



This work is licensed under a [Creative Commons Attribution 4.0 License](https://creativecommons.org/licenses/by/4.0/).

ABSTRACT

Background and Objectives: The emergence of extended-spectrum β -lactamase (ESBL)-producing *Shigella* spp. is becoming a health concern worldwide. This study aimed to investigate antibiotic resistance pattern and frequency of *bla*_{CTX-M}, *bla*_{SHV}, and *bla*_{TEM} genes among *Shigella* isolates from patients in hospitals of Tehran, Iran.

Methods: In this cross-sectional study, 52 non-repeated *Shigella* strains were isolated from hospitalized patients in Milad, Emam Khomeini and Shariati hospitals in Tehran (Iran) from November 2015 to December 2016. Bacterial identification, serotyping, and antimicrobial susceptibility testing were performed according to the standard guidelines. The *bla*_{CTX-M}, *bla*_{SHV}, and *bla*_{TEM} resistance genes were identified using multiplex polymerase chain reaction.

Results: Among 52 *Shigella* isolates, *S. sonnei* (44.2%) was the predominant species, followed by *S. flexneri* and *S. dysenteriae* (23%). Over 67% of the isolates were multidrug resistant. The highest rates of resistance were observed against cefalotin (67.3%), tetracycline (67.3%), amikacin (63.5%), trimethoprim-sulphamethoxazole (48.1), and ampicillin (42.3%). The lowest resistance rate was against ciprofloxacin (1.9%). We detected the *bla*_{TEM} and *bla*_{CTX-M} genes in 61.5% and 19.2% of the isolates, respectively. However, the *bla*_{SHV} gene was not detected in any of the isolates. In addition, 16.4% of the isolates harbored the *bla*_{TEM} and *bla*_{CTX-M} genes simultaneously. Ciprofloxacin was the most effective antibiotics according to the ESBL genes distribution.

Conclusion: Our findings indicate the high prevalence of multidrug resistance and ESBL genes in *Shigella* isolates, which elucidates the need for appropriate infection control measures for limiting the spread of resistant strains.

Keywords: *Shigella*, Multiplex Polymerase Chain Reaction, Drug Resistance.

INTRODUCTION

Shigellosis is a global human health problem and the leading cause of diarrhea, which results in about 700,000 deaths per year worldwide (1). Despite the recent public health improvements, incidence of shigellosis is still being reported regularly (2, 3). The genus *Shigella* belongs to the *Enterobacteriaceae* family and consists of four subgroups according to their biochemical and serological properties: A (*Shigella dysenteriae*), B (*Shigella flexneri*), C (*Shigella boydii*), and D (*Shigella sonnei*). All *Shigella* species can cause shigellosis, but *S. flexneri* and *S. sonnei* are the predominant causative agents in developing and industrialized countries, respectively (4).

Antibiotic therapy in patients with shigellosis can help reduce the duration of illness, shedding of the organism in the feces, and the risk of person-to-person spread. A range of antibiotics is effective for the treatment of shigellosis. However, treatment options are limited due to the emergence of multidrug-resistant (MDR) strains. The World Health Organization (WHO) has recommended ciprofloxacin as the first-line treatment (5), but increased resistance to this antibiotic and other fluoroquinolones has been reported in many countries (2, 6). Azithromycin, mecillinam, and ceftriaxone are also considered to be effective for treatment of shigellosis (5).

The emergence of resistance to third-generation cephalosporins (3GC) in *Shigella* spp. is an important public health concern, mainly in developing countries (7). Resistance to 3GC is largely due to production of extended-spectrum β -lactamases (ESBLs), which is often plasmid-mediated (8). Most ESBLs are derivatives of the TEM and SHV β -lactamase families, but CTX-M β -lactamases have also been associated with ESBL-producing strains. These β -lactamases show greater activity against cefotaxime than ceftazidime, but increased activity against ceftazidime can occur due to point mutations (9).

CTX-M, SHV, and TEM type ESBL producing *Shigella* species have been identified in different parts of the world (6, 8, 10). Studies on ESBL-producing *Shigella* isolates have revealed presence of insertion element upstream of the *bla*_{CTX-M} gene, which may contribute to the mobility and dissemination of the genes to other bacteria

(8). The frequency of ESBL-producing *Shigella* species is increasing in Iran (11, 12). According to studies in Iran, the prevalence of ESBL-producing *Shigella* strains is higher than the rates observed in many other countries (11, 13). Studying the role of these isolates in infectivity and continuous monitoring of ESBL genes may be beneficial for determining appropriate treatment and control strategies in Iran. Therefore, the present study was conducted to evaluate antibiotic susceptibility profiles and to screen the presence of *bla*_{TEM}, *bla*_{CTX-M}, and *bla*_{SHV} genes among clinical isolates of *Shigella*.

MATERIALS AND METHODS

This cross-sectional study was conducted between November 2015 and December 2016 at three teaching hospitals in Tehran, Iran. Stool samples were collected from patients admitted with symptoms of diarrhea prior to administration of antibiotics. Samples were immediately transferred to laboratory and then inoculated on xylose lysine deoxycholate agar (Merck, Germany). The plates were incubated at 37 °C for 24 hours and then *Shigella* suspected colonies were examined by conventional biochemical tests, including triple sugar iron agar, urea agar, SIM medium and IMVIC (indole, methyl red, Voges-Proskauer, and citrate) (14). Specific antisera (DIFCO, U.S.A) were used for serogrouping of *Shigella* isolates using a slide agglutination test (15). The study was approved by the Ethics Committee of Islamic Azad University of Tehran Medical Sciences (No: IR.IAU.TMU.REC.1396.275).

Antibiotic susceptibility testing was performed using the Kirby-Bauer disk diffusion method, according to CLSI guidelines (2017). The following antibiotic disks were used in the susceptibility testing: amikacin (30 μ g), tetracycline (30 μ g), nalidixic acid (30 μ g), ciprofloxacin (5 μ g), furazolidone (100 μ g), cefolatin (30 μ g), doxycycline (30 μ g), trimethoprim-sulfamethoxazole (25 μ g), cefazolin (30 μ g), gentamicin (120 μ g), ceftriaxone (30 μ g), and ceftazidime (30 μ g) (Mast Diagnostics, UK). In addition, *E. coli* ATCC 25922 was used as the control strain (16). To confirm ESBL production, combination disk test using cefotaxime and ceftazidime disks (30 μ g) with and without clavulanic acid (10 μ g) was carried out on

Mueller Hinton agar (Merck, Germany) according to CLSI guidelines. Growth inhibition zone around cefotaxime or ceftazidime disks combined with clavulanic acid was compared with that around cefotaxime or ceftazidime disks alone. Growth inhibition zone diameter of >5mm with clavulanic acid than without confirmed ESBL production (16).

Boiling method was used for extraction of DNA from pure colonies after an overnight growth of *Shigella* isolates on Luria-Bertani agar (Oxoid, UK). Concentration of the extracted DNA was assessed by a spectrophotometer (Genway, England). Multiplex polymerase chain reaction (PCR) was performed using specific primers for simultaneous detection of the *bla_{SHV}*, *bla_{CTX-M}*, and *bla_{TEM}* (Table 1). PCR reactions were carried out in a final volume of 25 µl containing 2 µl DNA solution, Master Mix (CinnaGen Co., Iran), and 10 pmol of each primer. PCR amplification conditions were as follows: initial denaturation at 95 °C for 15 min, 30 cycles of denaturation at 94 °C for 30 s, annealing at 60 °C for 30 s, extension at 72 °C for 2 min, followed by final extension at 72 °C for 10 min (17). *Klebsiella pneumoniae* ATCC 700603 was used as positive control. SPSS statistical software (version 20; SPSS Inc., Chicago, IL, USA) was used for data analysis. The chi-square test was used to

evaluate significant differences in antimicrobial resistance and the correlation between resistance genes and antibiotics resistance. A P-value of less than 0.05 was considered statistically significant.


RESULTS

Of 945 samples collected during the study period, 52 *Shigella* strains were isolated. Among these isolates, *S. sonnei* was the predominant species (n=23, 44.2%), followed by *S. flexneri* (n=12, 23%), *S. dysenteriae* (n=12, 23%), and *S. boydii* (n=5, 9.6%). Figure 1 shows the antimicrobial resistance patterns of *Shigella* isolates against the tested antibiotics. Highest rate of resistance was against cefalotin (67.3%), tetracycline (67.3%), amikacin (63.47%), trimethoprim-sulphamethoxazole (48.1), ampicillin (42.3%), and doxycycline (32.7%). Moderate to low rate of resistance was observed against nalidixic acid (23.1%), ceftriaxone (19.2%), azithromycin (11.5), ceftazidime (9.6%), gentamicin (11.5%), and ciprofloxacin (1.9%). The isolates showed intermediate resistance to doxycycline (26.9%), trimethoprim-sulphamethoxazole (23.1%), cefazoline (17.3%), and gentamicin (17.3%). All *Shigella* isolates were resistant to nalidixic acid, but all *S. flexneri*, *S. dysenteriae*, and *S. boydii* isolates were sensitive to ciprofloxacin.

Table 1- Sequence of the primers used in multiplex PCR

Genes	Oligonucleotide sequence (5' to 3')	Amplicon size (bp)	References
<i>bla_{SHV}</i>	ATGCGTTATATTCGCCTGTG TGCTTGTATTTCGGGCCAA	747	(18)
<i>bla_{TEM}</i>	TCGCCGCATACACTATTCTCAGAATGA ACGCTCACCGGCTCCAGATTAT	445	(17)
<i>bla_{CTX-M}</i>	ATGTGCAGCACCAGTAAAGTGATGGC TGGGTAAAGTAAGTGACCAGAATCAGCGG	593	(19)

Figure 1-Antibiotic susceptibility pattern of *Shigella* isolates to various antibiotics. Tri/Sul*: trimethoprim/sulfamethoxazole



Downloaded from gourms.ac.ir at 14:28 +0430 on Monday April 29th 2019 [DOI: 10.29252/mlj.13.2.8]

Strains resistant to three or more classes of antibiotics were identified as MDR (20). Multidrug resistance was detected in 15 (65.2%) *S. sonnei*, 10 (83.3%) *S. dysenteriae*, 8 (66.6%) *S. flexneri*, and 1 (20%) *S. boydii* isolates.

Multidrug resistance profiles of *Shigella* isolates are reported in Table 3. Phenotypic evidence of ESBL production was observed in 19 (36.5%) *Shigella* isolates, among which *S. dysenteriae* (7/12, 58.3%) was the predominant ESBL producer, followed by *S. flexneri* (4/12, 33.3%), *S. sonnei* (7/23, 30.4%), and *S. boydii* (1/5, 20%).

All 52 *Shigella* isolates were also tested for the presence of the *bla*_{TEM}, *bla*_{SHV}, and *bla*_{CTX-M} genes. All isolates were negative for *bla*_{SHV}, but 32 (61.54%) isolates harbored *bla*_{TEM}. Ten (19.23%) isolates contained *bla*_{CTX-M} and seven isolates (13.46%) carried both *bla*_{TEM} and *bla*_{CTX-M}. Figure 2 displays the PCR gel electrophoresis of the *bla*_{TEM}, *bla*_{CTX-M}, and *bla*_{SHV} genes. The frequency of *bla*_{TEM} was highest in *S. dysenteriae* (83.3%), followed by *S. sonnei* (60.87%). However, the frequency of simultaneous harboring of *bla*_{TEM} and *bla*_{CTX-M} was highest among *S. sonnei* isolates (Figure 3).

Figure 2- Multiplex PCR assay for detection of *bla*_{TEM}, *bla*_{CTX-M}, and *bla*_{SHV} on 1.5% agarose gel. Lane 1: negative control, lane 2-4: positive for *bla*_{TEM} and *bla*_{CTX-M}, lane 5-7: positive for *bla*_{TEM}, lane 8-10: positive for *bla*_{CTX-M}, and lane 11: positive control (*K. pneumoniae* ATCC 700603).





Figure 3- Frequency of the *bla*_{TEM}, *bla*_{CTX-M} and *bla*_{SHV} genes in *Shigella* isolates



All MDR *Shigella* strains carried at least one *bla* gene (Table 3). The results showed that all *bla*_{TEM}-containing *Shigella* strains were resistant to cefalotin, 75% were resistant to tetracycline, amikacin, and cefazolin, 72% were resistant to trimethoprim-sulfamethoxazole, and 55.5% were resistant to ampicillin and furazolidone. All *Shigella*

strains that simultaneously carried *bla*_{TEM} and *bla*_{CTX-M} were resistant to ampicillin, amikacin, tetracycline, nalidixic acid, furazolidone, cefalotin, doxycycline, trimethoprim-sulfamethoxazole, cefazolin, and ceftriaxone. Furthermore, only one strain harboring both *bla*_{TEM} and *bla*_{CTX-M} was resistant to ciprofloxacin (Table 2).

Table 2- Multidrug resistance profile of *Shigella* isolates (n=35) based on the distribution of *bla* genes

Antimicrobial resistance profiles	Number (%) of resistant isolates					ESBL genes
	Total (n=34)	<i>S. sonnei</i> (n=15)	<i>S. dysenteriae</i> (n=10)	<i>S. flexneri</i> (n=8)	<i>S. boydii</i> (n=1)	
AK/T/KF	1 (2.9)	0	1 (10)	0	0	<i>bla</i> _{TEM}
AK/T/FZ/KF	1 (2.9)	1 (6.7)	0	0	0	<i>bla</i> _{TEM}
AK/T/KF/TS/CZ	3 (8.8)	0	1 (10)	2 (25)	0	<i>bla</i> _{TEM}
AP/AK/T/KF/CZ	1 (2.9)	0	1 (10)	0	0	<i>bla</i> _{TEM}
AK/T/FZ/KF/CZ	2 (5.9)	2 (13.3)	0	0	0	<i>bla</i> _{TEM}
AK/T/FZ/KF/TS	1 (2.9)	0	1 (10)	0	0	<i>bla</i> _{TEM}
AP/AK/T/NA/KF	1 (2.9)	1 (6.7)	0	0	0	<i>bla</i> _{TEM}
FZ/KF/DX/TS/CZ	1 (2.9)	1 (6.7)	0	0	0	<i>bla</i> _{TEM}
AK/T/KF/CZ/CRO	1 (2.9)	1 (6.7)	0	0	0	<i>bla</i> _{TEM}
FZ/KF/DX/CZ/CRO	1 (2.9)	1 (6.7)	0	0	0	<i>bla</i> _{CTX-M}
AP/AK/T/FZ/KF/CZ	1 (2.9)	1 (6.7)	0	0	0	<i>bla</i> _{TEM}
AP/AK/T//KF/TS/CZ	1 (2.9)	0	0	1 (12.5)	0	<i>bla</i> _{TEM}
AK/T/FZ/KF/TS/CZ	1 (2.9)	0	0	1 (12.5)	0	<i>bla</i> _{TEM}
AK/T/KF/DX/TS/CZ	1 (2.9)	0	0	1 (12.5)	0	<i>bla</i> _{TEM}
AP/AK/T/FZ/KF/TS/CZ	4 (11.8)	2 (13.3)	1 (10)	1 (12.5)	0	<i>bla</i> _{TEM}
AP/AK/T/FZ/KF/DX/TS/CZ	2 (5.9)	0	2 (20)	0	0	<i>bla</i> _{TEM}
AP/AK/T/NA/FZ/KF/TS/CZ/	1 (2.9)	0	1 (10)	0	0	<i>bla</i> _{TEM}
AP/AK/T/NA/FZ/KF/DX/TS/CZ	1 (2.9)	1 (6.7)	0	0	0	<i>bla</i> _{TEM}
AP/AK/T/NA/FZ/KF/DX/TS/CZ/CRO	1 (2.9)	0	1 (10)	0	0	<i>bla</i> _{TEM} ; <i>bla</i> _{CTX-M}
AP/AK/T/NA/FZ/KF/DX/TS/CZ/GM/CRO	2 (5.9)	0	0	2 (25)	0	<i>bla</i> _{CTX-M}
AP/AK/T/NA/FZ/KF/DX/TS/CZ/CRO/CZA	1 (2.9)	1 (6.7)	0	0	0	<i>bla</i> _{TEM} ; <i>bla</i> _{CTX-M}
AP/AK/T/NA/FZ/KF/DX/TS/GM/CRO	1 (2.9)	0	1 (10)	0	0	<i>bla</i> _{TEM} ; <i>bla</i> _{CTX-M}
AP/AK/T/NA/FZ/KF/DX/TS/CZ/CRO/CZA	1 (2.9)	1 (6.7)	0	0	0	<i>bla</i> _{TEM} ; <i>bla</i> _{CTX-M}
AP/AK/T/NA/FZ/KF/DX/TS/CZ/GM/ CRO/CZA	1 (2.9)	0	0	0	1 (100)	<i>bla</i> _{TEM} ; <i>bla</i> _{CTX-M}
AP/AK/T/NA/CIP/FZ/KF/DX/TS/CZ/GM/CRO/CZA	2 (5.9)	2 (13.3)	0	0	0	<i>bla</i> _{TEM} ; <i>bla</i> _{CTX-M}

AK: amikacin, T: tetracycline, NA: nalidixic acid, C: ciprofloxacin, FZ: furazolidone, KF: cefolatin, DXT: doxycycline, TS: trimethoprim-sulfamethoxazole, CZ: cefazolin, GM: gentamicin, CRO: ceftriaxone, and CZA: ceftazidime.

DISCUSSION

Shigellosis is a major cause of morbidity and mortality among children in the developing countries (21). MDR *Shigella* isolates narrow the choice of effective antimicrobials and treatment options for shigellosis (22). Besides, with the advent of ESBL-producing *Shigella* strains, 3GC is no longer effective against MDR *Shigella*. Hence, knowledge about the contribution of the MDR strains to infectivity in hospitalized patients and continuous monitoring of the involved genes in different regions can be beneficial for development and implementation of preventive and control measures.

S. sonnei and *S. flexneri* are the most commonly isolated species in industrialized (23) and developing countries (24), respectively. In our study, *S. sonnei* was the most common cause of shigellosis, which is consistent with findings of other studies in Iran (25-27). Reasons behind the dominance of *S. sonnei* in industrialized countries remain unclear (28), but an increasing incidence of shigellosis caused by *S. sonnei* generally correlates with improving economic prosperity (29).

In our study, most *Shigella* isolates were resistant and intermediately resistant to trimethoprim-sulfamethoxazole and ampicillin, the first-line drugs suggested by the CLSI for shigellosis (30). These results are in line with the results of other studies (31, 32). Quinolones are a good choice for the treatment of shigellosis (30). However, more than 34% of *Shigella* isolates in our study were resistant and intermediately resistant to nalidixic acid. In a study by Ghavam et al. in Iran, a similar frequency for resistance to nalidixic acid was observed (26), but in some countries higher resistance rates have been reported (7, 31).

Multi-drug resistance to the antimicrobial agents used for the treatment of shigellosis has been reported in many parts of the world (31, 33, 34). The results of our study suggest that multidrug resistance is common amongst all *Shigella* species, and this property was more notable in the case of *S. dysenteriae*. Inappropriate prescription and the easy access to antibiotics among outpatients could facilitate the spread of MDR *Shigella* strains in the community (34).

In the case of infections caused by MDR strains, 3GC and fluoroquinolones are used for treatment of children and adults, respectively

(35). We detected very little resistance to ciprofloxacin (1.92%), which is comparable with the results of other studies in Iran (12, 27, 36). However, a higher prevalence for ciprofloxacin-resistant *Shigella* isolates has been documented in other countries (31, 33, 34). In our study, the rate of resistance to ceftriaxone was 19.23%, which is higher than the rates reported by studies in Iran (11, 27, 37) and other countries (31, 38). However, even higher prevalence rates for ceftriaxone resistance among *Shigella* isolates has been reported in China (39). We also observed simultaneous resistance to ciprofloxacin and ceftriaxone, which further limits therapeutic options.

In a study by Pourakbari and colleagues, *S. sonnei* was more sensitive to cephalosporines (ceftizoxime, ceftriaxone, ceftazidime, and cephalothin) than *S. flexneri*, and *S. flexneri* was more sensitive to nalidixic acid than *S. sonnei* (40). Contrary to these findings, we found no significant difference in antibiotic susceptibility among *S. sonnei* and *S. flexneri* isolates.

In recent years, a high frequency of *TEM* gene has been identified in *Shigella* and other *Enterobacteriaceae* (22). This is of great clinical importance because the gene confers resistance to ampicillin, which was the principal antibiotic used for treatment of shigellosis (41). In our study, the *bla*_{TEM} gene was detected in 61.5% of the *Shigella* isolates and in all MDR strains. Ampicillin resistance was found to be significantly associated with *TEM* β -lactamase genes in all isolates, which is in agreement with the results of other studies (10, 42). Ampicillin resistance in *S. flexneri* and *S. sonnei* is mainly due to the presence of *bla*_{OXA} and *bla*_{TEM}, respectively (42). Likewise, we found a significant correlation between ampicillin resistance and presence of *bla*_{TEM} in *S. sonnei* isolates. However, no significant relationship was found between resistance to ampicillin and presence of *bla*_{TEM} in *S. flexneri* isolates.

In the present study, the frequency of *bla*_{CTX-M} was relatively high among *Shigella* isolates. Zahedi Bialvaei et al. reported an even higher frequency for the *bla*_{CTX-M} gene (12). Among the *Shigella* isolates, *bla*_{CTX-M} was more frequently found in *S. sonnei* (21.74%), which is higher (33, 43) and in one case lower (23)

than the frequencies reported by studies in other countries. This could be because the transfer of the *bla*_{CTX-M} gene is plasmid-mediated.

To the best of our knowledge, this is the first report on the emergence of simultaneous resistance to ceftriaxone and ciprofloxacin among *bla*_{CTX-M}-positive *Shigella* isolates in Iran. With the increase in globalization, the potential widespread dissemination of these strains could be a public health threat, not only in Iran but also in the rest of the world. Therefore, effective infection control policies are needed for preventing the dissemination of resistant strains. Phage-based control of shigellosis can be considered as an alternative strategy for the treatment of MDR *Shigella* strains (44).

REFERENCES

- Tai AY, Easton M, Encena J, Rotty J, Valcanis M, Howden BP, et al. *A review of the public health management of shigellosis in Australia in the era of culture independent diagnostic testing*. Aust N Z J Public Health. 2016; 40: 588-91.
- Kim JS, Kim JJ, Kim SJ, Jeon SE, Seo KY, Choi JK, et al. *Outbreak of Ciprofloxacin-Resistant Shigella sonnei Associated with Travel to Vietnam, Republic of Korea*. Emerg Infect Dis. 2015; 21(7): 1247-50.
- Kozyreva VK, Jospin G, Greninger AL, Watt JP, Eisen JA, Chaturvedi V. *Recent Outbreaks of Shigellosis in California caused by two distinct populations of Shigella sonnei with either increased virulence or fluoroquinolone resistance*. mSphere. 2016; 21;1(6). doi: 10.1128/mSphere.00344-16.
- Livio S, Strockbine NA, Panchalingam S, Tennant SM, Barry EM, Marohn ME, et al. *Shigella isolates from the global enteric multicenter study inform vaccine development*. Clin Infect Dis. 2014; 59 (7): 933-41.
- World Health Organization. *Guidelines for the Control of Shigellosis, including epidemics due to Shigella dysenteriae type 1*. Geneva: WHO; 2005.
- Qiu S, Xu X, Wang Y, Yang G, Wang Z, Wang H, et al. *Emergence of resistance to fluoroquinolones and third-generation cephalosporins in Shigella flexneri subserotype 1c isolates from China*. Clin Microbiol Infect. 2012 ;18 (4): E95-8. doi: 10.1111/j.1469-0691.2012.03768.x.
- Zhang R, Zhou HW, Cai JC, Zhang J, Chen GX, Nasu M, et al. *Serotypes and extended-spectrum β -lactamase types of clinical isolates of Shigella spp. from the Zhejiang province of China*. Diagn Microbiol Infect Dis. 2011; 69: 98-104.
- Sabra AH, Araj GF, Kattar MM, Abi-Rached RY, Khairallah MT, Klena JD, et al. *Molecular characterization of ESBL-producing Shigella sonnei isolates from patients with bacillary dysentery in Lebanon*. J Infect Dev Ctries. 2009; 3(4): 300-05.

CONCLUSION

We revealed the high prevalence of *bla*_{TEM} and *bla*_{CTX-M} in *Shigella* strains isolated from patients in Iran. Antimicrobial susceptibility testing also demonstrated the high level of multi-drug resistance among these isolates. These findings raise serious concerns about the dissemination of ESBL-producing *Shigella* strains, and emphasize the need for controlled use of antibiotics, especially 3GC, to avoid further antibiotic resistance.

ACKNOWLEDGEMENTS

This article has been derived from an MSc thesis, funded by the Islamic Azad University, Islamshahr Branch, Iran.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

- Manoharan A, Premalatha K, Chatterjee S, Mathai D. *Correlation of TEM, SHV and CTX-M extended-spectrum beta lactamases among Enterobacteriaceae with their in vitro antimicrobial susceptibility*. Indian J Med Microbiol. 2011; 29(2): 161-4.
- Taneja N, Mewara A, Kumar A, Verma G, Sharma M. *Cephalosporin-resistant Shigella flexneri over 9 years (2001-09) in India*. J Antimicrob Chemother. 2012; 67: 1347-53.
- Ranjbar R, Mirsaeed Ghazi F, Shohreh Farshad S, Giammanco GM, Aleo A, Owlia P, et al. *The occurrence of extended-spectrum β -lactamase producing Shigella spp. in Tehran, Iran*. Iran J Microbiol. 2013; 5 (2): 108-112.
- Zahedi Bialvaei A, Poulak T, Aghamali M, Asgharzadeh M, Gholizadeh P, Samadi Kafil H. *The prevalence of CTX-M-15 extended spectrum β -lactamases among Salmonella spp. and Shigella spp. isolated from three Iranian hospitals*. Eur J Microbiol Immunol. 2017; 7(2): 133-7.
- Akhi MT, Bialvaei A, Ghotaslou R, Asgharzadeh M, Naghili B, Pirzadeh T, et al. *Faecal carriage of ESBL and plasmidmediated AmpC β -lactamase genes in Klebsiella spp. and Shigella spp. isolated from inpatient and outpatient carriers in Tabriz, Iran*. Int J Fund Appl Sci. 2016; 8: 16-29.
- Barrow GI, Feltham RKA. *Cowan and Steel's Manual for the Identification of Medical Bacteria*. Cambridge University Press, 2005.
- Lefebvre J, Gosselin F, Ismaïl J, Lorange M, Lior H, Woodward D. *Evaluation of commercial antisera for Shigella serogrouping*. J Clin Microbiol. 1995; 33(8): 1997-2001.
- Wayne P. *Performance standards for antimicrobial susceptibility testing*. Clinical and Laboratory Standards Institute (CLSI) 27th informational supplement M100, 2017.

17. Monstain HJ, Ostholm- Balkhed A, Nilsson MV, Nilsson M, Dornbusch K, Nilsson LE. *Multiplex amplification assay for detection of blaSHV, blaTEM and blaCTX-m genes in Enterobacteriaceae*. APMIS. 2007; 115: 1400-8.
18. Paterson DL, Hujer KM, Hujer AM, Yeiser B, Bonomo MD, Rice LB, et al. *Extended-spectrum beta-lactamases in Klebsiella pneumonia bloodstream isolates from seven countries: dominance and widespread prevalence of SHV-and CTX-M-type beta-lactamases*. Antimicrob Agents Chemother. 2003; 47: 3553-60.
19. Boyd DA, Tyler S, Christianson S, McGeer A, Muller MP, Willey BM, et al. *Complete nucleotide sequence of a 92-kilobase plasmid harboring the CTX-M-15 extended-spectrum beta-lactamase involved in an outbreak in long-term-care facilities in Toronto, Canada*. Antimicrob Agents Chemother. 2004; 48: 3758-64.
20. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. *Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance*. Clin Microbiol Infect. 2012; 18: 268-81.
21. Gupta S, Mishra B, Muralidharan S, Srinivasa H. *Ceftriaxone resistant Shigella flexneri, an emerging problem*. Ind J Med Sci. 2010; 64: 553-6.
22. Yang C, Li P, Zhang X, Ma Q, Cui X, Li H, et al. *Molecular characterization and analysis of high-level multidrug-resistance of Shigella flexneri serotype 4s strains from China*. Sci Rep. 2016; 6: 29124. doi: 10.1038/srep29124.
23. Zhang CL, Liu QZ, Wang J, Chu X, Shen LM, Guo YY. *Epidemic and virulence characteristic of Shigella spp. with extended-spectrum cephalosporin resistance in Xiaoshan District, Hangzhou, China*. BMC Infect Dis. 2014; 14: 260. doi: 10.1186/1471-2334-14-260.
24. Sethuvel DPM, Rajupathi NKD, Anandan S, Veeraraghavan B. *Update on: Shigella new serogroups/serotypes and their antimicrobial resistance*. Lett Appl Microbiol 2016; 64: 8-18.
25. Alizadeh-Hesar M, Bakhshi B, Najari-Peerayeh S. *Clonal dissemination of a single Shigella sonnei strain among Iranian children during fall 2012 in Tehran, I.R. Iran*. Infect Genet Evol. 2015; 34: 260-6.
26. Ghavam P, Monajemzadeh M, Haghi Ashtiani M T, Mamishi S, Nodeh Farahani N, Tanzifi P. *Shigellosis and Changes of Antimicrobial Susceptibility During Six Years*. Iran J Pediatr. 2017; 27(3): e5131. doi: 10.5812/ijp.5131.
27. Tajbakhsh M, García Migura L, Rahbar M, Svendsen CA, Mohammadzadeh M, et al. *Antimicrobial resistant Shigella infections from Iran: an overlooked problem?* J Antimicrob Chemother. 2012; 67(5): 1128-33.
28. Keusch GT. *Bacterial Infections of Humans*. Brachman PS, Abrutyn E, editors Boston, MA: Springer US, 2009.
29. Ram P, Crump J, Gupta S, Miller M, Mintz E. *Part II. Analysis of data gaps pertaining to Shigella infections in low and medium human development index countries, 1984-2005*. Epidemiol Infect. 2008; 136: 577-603.
30. Wayne P. *Performance standards for antimicrobial susceptibility testing*. Clinical and Laboratory Standards Institute (CLSI) 16th informational supplement M100-S16, 2006.
31. Aggarwal P, Uppal B, Ghosh R, Krishna Prakash S, Chakravarti A, Jha AK, et al. *Multi drug resistance and extended spectrum beta lactamases in clinical isolates of Shigella: A study from New Delhi, India*. Travel Medicine and Infectious Disease. 2016; 14(4): 407-13.
32. Shiferaw B, Solghan S, Palmer A, Joyce K, Barzilay EJ, Krueger A, et al. *Antimicrobial susceptibility patterns of Shigella isolates in foodborne diseases active surveillance network (FoodNet) sites, 2000-2010*. Clin Infect Dis. 2012; 54(5): 458-63.
33. Nüesch-Inderbinen M, Heini N, Zurfluh K, Althaus D, Hächler H, Stephan R. *Shigella antimicrobial drug resistance mechanisms, 2004-2014*. Emerg Infect Dis. 2016; 22(6): 1083-5.
34. Zhang W, Luo Y, Li J, Lin L, Ma Y, Hu C, et al. *Wide dissemination of multidrug-resistant Shigella isolates in China*. J Antimicrob Chemother. 2011; 66: 2527-35.
35. Acikgoz ZC, Eser OK, Kocagoz S. *CTX-M-3 type beta-lactamase producing Shigella sonnei isolates from pediatric bacillary dysentery cases*. Jpn J Infect Dis. 2008; 61: 135-7.
36. Nikfar R, Shamsizadeh A, Darbor M, Khaghani S, Moghaddam M. *A Study of prevalence of Shigella species and antimicrobial resistance patterns in paediatric medical center in Ahvaz, Iran*. j microbial. 2017; 9(5): 277-82.
37. Khaghani S, Shamsizadeh A, Nikfar R, Hesami A. *Shigella flexneri: a three-year antimicrobial resistance monitoring of isolates in a Children Hospital, Ahvaz, Iran*. Iran j microbial. 2014; 6(4): 225-9.
38. Zaidi MB, Estrada-García T, Campos FD, Chim R, Arjona F, Leon M, et al. *Incidence, clinical presentation, and antimicrobial resistance trends in Salmonella and Shigella infections from children in Yucatan, Mexico*. Front Microbiol. 2013; 4: 288. doi: 10.3389/fmicb.2013.00288.
39. Cui X, Yang C, Wang J, Liang B, Yi S, Li H, et al. *Antimicrobial Resistance of Shigella flexneri Serotype 1b Isolates in China*. PLOS ONE 2015; 10(6): e0129009. doi: 10.1371/journal.pone.0129009.
40. Pourakbari B, Mamishi S, Mashoori N, Mahboobi N, Ashtiani MH, Afsharpaiman S, et al. *Frequency and antimicrobial susceptibility of Shigella species isolated in Children Medical Center Hospital, Tehran, Iran, 2001-2006*. Braz J Infect Dis. 2010; 14(2): 153-7.
41. Klontz KC, Singh N. *Treatment of drug-resistant Shigella infections*. Expert Rev Anti Infect Ther. 2015; 13: 69-80.
42. Toro CS, Farfan M, Contreras I, Flores O, Navarro N, Mora GC, et al. *Genetic analysis of antibiotic resistance determinants in multidrug-resistant Shigella strains isolated from Chilean children*. Epidemiol Infect. 2005; 133: 81-6.
43. Kacmaz B, Unaldi O, Sultan N, Durmaz R. *Drug resistance profiles and clonality of sporadic Shigella sonnei isolates in Ankara, Turkey*. Braz J Microbiol. 2014; 45(3): 845-9.
44. Shahin K, Bouzari M, Wang R. *Isolation, characterization and genomic analysis of a novel lytic bacteriophage vB_SsoS-ISF002 infecting Shigella sonnei and Shigella flexneri*. J Med Microbiol. 2018; 67(3): 376-386.